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ABSTRACT 
 
The prediction and understanding of acetaminophen (APAP)- induced liver injury 
(APAP-ILI) and the response to therapeutic interventions is complex. This is due in 
part to sensitivity and specificity limitations of currently used assessment techniques. 
Here we sought to determine the utility of integrating translational non- invasive 
photoacoustic imaging of liver function with mechanistic circulating biomarkers of 
hepatotoxicity with histological assessment to facilitate the more accurate and precise 
characterization of APAP-ILI and the efficacy of therapeutic intervention. 
Perturbation of liver function and cellular viability was assessed in C57BL/6J male 
mice by Indocyanine green (ICG) clearance (Multispectral Optoacoustic Tomography 
(MSOT)) and by measurement of mechanistic (miR-122, HMGB1) and established 
(ALT, bilirubin) circulating biomarkers in response to the acetaminophen and its 
treatment with acetylcysteine (NAC) in vivo. We utilized a 60% partial hepatectomy 
model as a situation of defined hepatic functional mass loss to compared 
acetaminophen- induced changes to. 
Integration of these mechanistic markers correlated with histological features of 
APAP hepatotoxicity in a time-dependent manner. They accurately reflected the onset 
and recovery from hepatotoxicity compared to traditional biomarkers and also 
reported the efficacy of NAC with high sensitivity. ICG clearance kinetics correlated 
with histological scores for acute liver damage for APAP (i.e 3h timepoint; r =0.90, 
P<0.0001) and elevations in both of the mechanistic biomarkers, miR-122 (e.g. 6h 
timepoint; r=0.70, P=0.005) and HMGB1 (e.g. 6h timepoint; r = 0.56, P=0.04). 
For the first time we report the utility of this non- invasive longitudinal imaging 
approach to provide direct visualisation of the liver function coupled with mechanistic 
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biomarkers, in the same animal, allowing the investigation of the toxicological and 
pharmacological aspects of APAP-ILI and hepatic regeneration. 
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INTRODUCTION 
Drug-induced liver injury (DILI) is a frequent cause for safety concern in preclinical 
and clinical drug development. It is also a leading cause of post-market withdrawal 
leading to regulatory action. Acute liver failure (ALF) is a feared complication of 
DILI, carrying a high risk of morbidity and mortality (Reuben et al., 2016). A lack of 
sensitivity, specificity and an indirect mechanistic basis of currently used circulating 
biomarkers and assessment methods of hepatic injury has been widely cited as a 
significant factor for limited predictivity and understanding of DILI (Clarke et al., 
2016; Antoine and Dear, 2017). Development of an experimental “toolbox” that 
encompasses the measurement of mechanistic events and changes in liver function 
alongside the viability and activity of both parenchymal and non-parenchymal cells in 
a non- invasive, time dependent and longitudinal way could prove essential for the 
detection, aetiological diagnosis, and prediction and monitoring of potential 
therapeutic interventions for DILI. Additionally, the validation of the non- invasive 
imaging assessment of liver function that can be repeated in individual animals would 
overcome limitations in preclinical studies such as small blood volumes and obtaining 
liver tissue following sacrifice. 
Clinical and preclinical studies of DILI have identified and developed circulating 
biomarkers that provide enhanced hepatic specificity (microRNA-122; miR-122) and 
provide information on mechanistic events such as hepatocyte necrosis (keratin-18), 
apoptosis (caspase-cleaved keratin-18), mitochondrial dysfunction (glutamate 
dehydrogenase), induction of inflammation (acetyl-High Mobility Group Box 1; 
acetyl-HMGB1) and regeneration (Colony Stimulating Factor 1; CSF-1) (Wang et al., 
2009; Starkey Lewis et al., 2011; Antoine et al., 2012; McGill et al., 2012; Stutchfield 
et al., 2015). Moreover, specific subsets of these mechanistic markers have also been 
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demonstrated to allow early identification of liver injury (miR-122) and can support 
enhanced prognostic determination in man (acetyl-HMGB1, CSF-1) (Antoine et al., 
2012; Antoine et al., 2013; Stutchfield et al., 2015). Although these key attributes 
have been recognised as fundamental to efforts in translational hepatotoxicity research 
and have gain support by drug regulators (EMA, 2016; FDA, 2016), many of the 
reported candidate biomarkers for hepatic drug safety have focused on hepatocyte 
injury rather than liver function. Despite its highly specialized function, the liver is 
unique in its capacity to adapt to chemical insults (Aleksunes et al., 2008; Eakins et 
al., 2015) and to regenerate after massive liver resection (Riehle et al., 2011). The 
ability of the liver to functionally cope with metabolic needs in different life 
threatening scenarios open a door to novel assessments directed towards the analysis 
and quantification of the remaining functional liver mass rather than the irreversible 
hepatic dead mass. 
The elimination of the water-soluble, hydrophobic organic anion, FDA approved dye 
Indocyanine green (ICG) is dependent upon its non-ATP-dependent transport by 
organic anion transporting polypeptides (OATPs) and sodium-taurocholate co-
transporting polypeptide (NTCPs) (de Graaf et al., 2011) into the hepatic parenchyma 
and excretion into the bile through ATP-dependent transporters multidrug resistance 
P-glycoprotein (Mdr2) and multidrug resistance-associated protein (Mrp2) (Wheeler 
et al., 1958; Huang and Vore, 2001). This dye mainly binds to plasma proteins 
(albumin and α1-lipoproteins) after intravenous administration without any 
extravascular distribution and without entering into the enterohepatic circulation is 
mainly taken by the hepatocytes and without any metabolic change is excreted into 
the gallbladder (Sakka et al., 2002; Olmedilla et al., 2009). Due to its exclusive 
hepatic clearance, the ICG elimination rate has been widely used to assess hepatic 
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blood flow, hepatosplanchnic haemodynamics, and liver function (Imamura et al., 
2005; Sakka, 2007; Levesque et al., 2016).  
The non- invasive and dynamic assessment of ICG clearance in vivo has recently been 
made possible through the development of multispectral optoacoustic tomography 
(MSOT). This novel non- invasive imaging modality exhibits improved resolution and 
optical imaging sensitivity combined with excellent temporal resolution and deep 
tissue penetration depth (Wang et al., 2003; Zhang et al., 2006). Recent applications 
have revealed its utility for in vivo imaging in oncology (McNally et al., 2016), 
human vasculature (Taruttis et al., 2016), neurology (Dima et al., 2014) and 
nephrotoxicity (Scarfe et al., 2015) applications as well as in the clinic for the non-
invasive imaging of Crohn's disease and assessment of the metastatic status in 
melanoma (Stoffels et al., 2015; Waldner et al., 2016).  
Therefore, the purpose of this investigation was to establish for the first time an 
experimental “tool box” that uses a novel non- invasive, dynamic imaging modality to 
assess hepatic function, providing additional insights beyond the classical serum 
markers of liver damage and allowing the preclinical stratification for entry into 
studies for assessing utility of therapeutic interventions.  Using APAP as a model 
hepatotoxin, the aim of these studies is to integrate this approach with mechanistic 
circulating biomarkers of hepatotoxicity, that have enhanced sensitivity and 
specificity, alongside traditional histopathological evaluation to potentially enhance 
the understanding and prediction of the onset and recovery from DILI and the 
response to therapeutic interventions. 
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MATERIALS AND METHODS 
Animal treatment 
All animals received humane care and the protocols described were in accordance 
with criteria outlined in a license granted under the Animals (Scientific Procedures) 
Act 1986 and approved by the University of Liverpool Animal Ethics Committee. 
Acetaminophen (APAP) was chosen as a hepatotoxin model and male C57BL/6J mice 
(Charles River, Margate, UK), aged seven to eight weeks were used. These were 
group housed (n = 5) with free access to food and water with a seven-day 
acclimatization period. Animals were fasted for 14 h prior to APAP dosing. For the 
time course study, groups of randomly selected animals were administered 300 mg/kg 
of APAP (Sigma Aldrich, UK) in 0.9 % saline (Braun, Melsungen, Germany) or 0.9 
% saline (control) with a single intraperitoneal (i.p.) injection. Mice were imaged at 3 
h (control, n = 10; APAP, n = 10), 6 h (control, n = 5; APAP, n = 10), 24 h (control, n 
= 5, APAP, n = 10), 48 h (control, n = 4; APAP, n = 6), 72 h (control, n = 4 
euthanised; APAP, n = 6) and 96 h (control, n = 5; APAP, n = 5) post APAP dosing 
and euthanized immediately after imaging.. Timepoints were selected according to the 
insignificant changes in circulating biomarkers seen in previous studies before 3 h 
(Antoine et al., 2009) and the full recovery seen at 96 h in the histological 
examination, the gold standard technique to diagnose liver disease (Tannapfel et al., 
2012).  
In order to preclinically test the utility of MSOT imaging to monitor liver function 
non- invasively and repeatedly in a small cohort, another group of mice (n = 5) was 
imaged throughout the same timeline after APAP administration and animals were 
only euthanized at the end of the course (96 h).  
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Additionally, to examine the capacity of MSOT to report the efficacy of established 
therapeutics, a cohort of mice was treated with 500 mg/kg of acetylcysteine (NAC) in 
phosphate-buffered saline (PBS) pH = 7, 1 h after APAP dose, imaged at 6 h (n = 10) 
and 24 h (n = 10) post APAP dosing and euthanised immediately after. 
Partial Hepatectomy surgery procedure 
Partial hepatectomy (PH) was used as a known volume of functional hepatic mass 
loss to compare with the effect of APAP and its amelioration with NAC. Mice (n = 5 
per group) were group housed (n= 5) with free access to food and water with a seven-
day acclimatisation period. Mice underwent surgery under sterile conditions. A 
midline laparotomy incision was drawn to expose the xiphoid process. The falciform 
ligament was divided and the median and left lateral liver lobes externalised. Lobes 
were ligated at the base of each lobe using 4/0 silk ties and removed. The peritoneum 
and the skin were closed using 6-0 Vicryl™ sutures. Mice received subcutaneous 
injections of Buprenorphine (0.05 mg/kg) as analgesia. Sham operation was 
performed in a cohort of mice (n = 5) as a control group where animals underwent the 
same procedure as the PH mice, without removing the liver lobes. These animals were 
then imaged to assess liver volume by means of magnetic resonance imaging (MRI) 
and liver function by means of MSOT imaging at day 1, 2, 3 and 7 after surgery. 
Liver volume was assessed by MRI until day 10 after surgery where full recovery of 
hepatic volume was observed (data not shown). 
Circulating biomarker measurements and histological examination 
Animals were euthanised by rising CO2 inhalation and blood was collected by cardiac 
puncture. Blood samples were stored at 4°C and allowed to clot for 30 min, then 
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separated into serum (2,000 x g, 10 min, 4 °C). ALT, miR-122 and total HMGB1 
were measured as previously described (Antoine et al., 2009; Antoine et al., 2010; 
Starkey Lewis et al., 2011; Antoine et al., 2012; Antoine et al., 2013). Serum ALT 
activity was determined by kinetic assay according to the manufacturer’s instructions 
(Thermo Fisher) and assayed on a Varioskan Flash machine (Thermo Fisher). MiR-
122 was extracted and purified using a miRNeasy kit followed by an RNeasy 
MiniElute Cleanup Kit (Qiagen, Venlo, Netherlands), in accordance with the 
manufacturer’s instructions. Reverse transcription was performed using the TaqMan 
miRNA reverse transcription kit (Applied Biosystems) and miR-22 (and U6 as an 
endogenous control according to previous published data) primers using a GeneAmp 
PCR9700 machine and qPCR reactions were run using Taqman PCR primers and 
Master mix (Applied Biosystems) on a ViiA7 machine (Life Technologies). Total 
HMGB1 measurement was determined by sandwich ELISA according to the 
manufacturer’s instructions (Shino-Test/IBL international) and total bilirubin (TBIL) 
was measured using a Bilirubin Assay Kit (Sigma-Aldrich) following the 
manufacturer’s instructions. Livers were removed, and the left lateral lobe fixed in 
10% neutral buffered formalin for approximately 48 h and routinely paraffin wax 
embedded. Consecutive sections (3-5 µm) were prepared and routinely stained with 
haematoxylin-eosin (HE) and subjected to the Periodic Acid Schiff (PAS) reaction for 
the demonstration of glycogen within hepatocytes, respectively. They were 
histologically assessed for any pathological changes and the APAP-induced 
hepatotoxic changes scored blindly as previously described and summarized in 
supplementary figure 1 (Antoine et al., 2009; Antoine et al., 2010). The score for 
hepatocyte necrosis (drug- induced liver injury score; DILI score) for each animal was 
based on the average of all lobules in the liver section (0: no necrosis; 1: necrosis 
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present, but ≤ 25 % of the lobules affected; 2: > 25 ≤ 50% of the lobules affected; 3: > 
50 of the lobules affected; 4: ≤ 75% of the lobules affected; 5: > 75% of the lobules 
affected). This scoring was then used to correlate the degree of liver injury and ICG 
half- life in the mice at 6 h, 24 h, 48 h, 72 h and 96 h post dosing. In the mice 
examined at 3 h post APAP dosing, a score was established reflecting the extent of 
centrilobular hydropic degeneration (HD) (score for degenerative changes) based on 
the number of the innermost centrilobular hepatocyte layers that were affected (1: 1-2 
layers with HD; 2: 2-3 layers with HD; 3: 3-4 layers with HD; 3.5: 3-5 layers with 
HD; 4: 4-5 layers with HD), again, an average score was determined for each mouse.  
Determination of total hepatic Glutathione (GSH)  
Total GSH content was quantified by the 5-5’-Dithiobis (2-nitrobenzoic acid) 
(DTNB)-based ‘recycling’ method as previously described (Owens and Belcher, 
1965). Hepatic GSH was measured by homogenizing weighed mouse liver samples 
(30-50 mg) in 800 µl of a buffered solution containing 6.3 mM EDTA and 143 mM 
NaH2PO4, pH 7.4 and 200 µl of 6.5 % (w/v) SSA.  The solution was centrifuged at 
14,000 rpm for 5 min. The pellets were dissolved in 1 M NaOH at 60 °C for 1 h and 
reserved for protein concentration determination by the method of Brad ford using 
Bio-Rad protein assay at 570 nm (Bradford, 1976). The supernatants were used to 
measure GSH concentration spectromically (at 412 nm) by kinetic reaction between 
total GSH and glutathione reductase on a MRX microtiter-plate reader with Max 
Revelation software (Dynatech Laboratories, Billinghirst, UK) as described 
previously (Williams et al., 2007).  GSH was compared to a 0-40 nmol/ml standard 
curve. 
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ICG clearance measurement by means of multispectral optoacoustic tomography 
(MSOT) 
For optoacoustic imaging, an MSOT inVision 256-TF small animal imaging system 
(iThera Medical GmbH, Munich, Germany) was used (Morscher et al., 2014). Briefly, 
a tunable optical parametric oscillator (OPO) pumped by an Nd:YAG laser provides 
excitation pulses with a duration of 9 ns at wavelengths from 680 nm to 980 nm at a 
repetition rate of 10 Hz with a wavelength tuning speed of 10 ms and a peak pulse 
energy of 100 mJ at 730 nm. Ten arms of a fiber bundle provide even illumination of 
a ring-shaped light strip of approximately 8 mm width. For ultrasound detection, 256 
toroidally focused ultrasound transducers with a center frequency of 5 MHz (60 % 
bandwidth), organized in a concave array of 270 degree angular coverage and a radius 
of curvature of 4 cm, were used. 
ICG (Pulsion Medical Systems, Germany) stock (5 mg/ml in sterile dH2O) was 
diluted in 0.9 % saline to 40 nmol in a final volume of 200ul for blood vessel 
imaging. At 3, 6, 24, 48, 72 and 96 h after APAP or saline administration, mice were 
anaesthetised (isoflurane) and had hair removed by shaving and depilatory cream 
from the abdominal and lumbar region. They were then imaged in the inVision 256-
TF MSOT imaging system. This was performed using a multispectral protocol for 23 
min. The acquisition rate was 10 frames per second using wavelengths 700, 730, 760, 
800, 850 and 900 nm. Ten consecutive frames were averaged to minimise motion-
induced perturbations in the image quality. After 3 min of baseline imaging, the mice 
received 220 μ l (40 nmol) ICG fluorescent dye in 0.9 % saline through a tail vein 
cannula over a period of 10 s. Following this the imaging data was continuously 
acquired for another 20 min. Data was reconstructed using ViewMSOTTM using a 
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back projection algorithm with impulse response and multispectral processing 
performed using linear regression with ICG, and oxy- and deoxy-hemoglobin spectra 
to resolve signals for the ICG dye, including gradient scaling for each animal at a time 
prior to the injection of the ICG. Regions of interest (ROIs) drawn around the 
ischiatic vessels of each mouse were used to determine the mean peak pixel inte nsity 
value (MSOT arbitrary units). The MSOT signal over time for mean ischiatic vessel 
pixel intensities was fitted in the PK GUI_v6_04 MSOT software program to an 
exponential decay model to determine the characteristic excretion half- life and rate 
constant. 
Statistical analyses 
Pearson and Spearman correlation coefficients models were applied to test whether 
the type and extent of the histological changes and the serum biomarker fluctuations 
were correlated with ICG measurements. Standard error of the mean was measured 
for all the different groups and parameters. Independent t-tests and one way ANOVA 
test were used when applied to compare measures of liver impairment, serum 
biomarker changes and quantitative histological scores at different time points 
between the control and the treatment group. The assumption of normality of variance 
was previously assessed and post hoc test was applied accordingly (Tukey).  
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RESULTS 
Characterisation of the time course of acetaminophen hepatotoxicity by novel 
and established circulating biomarkers and histopathology 
To induce DILI we utilised our previously reported and well-established murine 
model of APAP-hepatotoxicity (Lundback et al., 2016). To assess the time course of 
liver injury, we measured serum ALT activity and total bilirubin (TBIL) as well as 
liver-enriched miR-122 and total high-mobility group box-1 protein (HMGB1) in sera 
and performed a histopathological evaluation of the livers. Significant elevations in 
ALT (1055.8±208.6 U/I), TBIL (0.74±0.04 mg/dL), miR-122 (10028.1 ±5151.6 U6 
normalised) and HMGB1 (141.5±27.6 ng/ml) were evident as early as 3 h after APAP 
dosing (Figure 1A-D); at this point, evidence of centrilobular hepatocyte death was 
restricted to apoptosis of rare individual hepatocytes. However, there was evidence of 
complete hepatocellular loss of glycogen in the parenchyma (Figure 1E). The 
innermost centrilobular hepatocyte layers (up to 5 layers) exhibited hydropic 
degeneration, a feature consistent with cell damage (Figure 1E).  By 6 h post dosing, 
when the histological examination revealed substantial hepatocyte death (coagulative 
necrosis; median score 2; Figure 1E), miR-122 levels and serum ALT activity had 
increased further, whereas TBIL and HMGB1 levels had already dropped 
substantially. Both showed a further decrease at 24 h post dosing, when miR-122 
levels had also dropped and only ALT exhibited peak values (3401.7±607.9 U/l). At 
this point, the histological picture was similar to that at 6 h (median score 2.25), 
though there was in general evidence of glycogen restitution outside affected areas 
(Figure 1E). By 48 h, necrotic hepatocytes were less numerous (median score 1) and 
intermingled with small (new) hepatocytes, there was also mild to moderate 
neutrophil-dominated leukocyte infiltration stretching from central veins into the 
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adjacent sinuses. Outside affected areas, the parenchyma exhibited full glycogen 
restitution (Figure 1E). At 72 and 96 h, necrotic cells were not observed anymore, 
centrilobular areas were increasingly cell rich, and several mitotic hepatocytes were 
observed, all consistent with resolution of liver damage by regeneration. Also, there 
was a variable amount of infiltrating leukocytes in particular at 96 h (Figure 1E). A 
decreasing trend in all biomarkers was observed over the time course assessed, with 
miR-122 and HMGB1 concentrations returning to baseline values by 72 and 96 h. 
However, although ALT and TBIL had decreased by 96 h, these values were still 
statistically significantly higher than those of control mice (Figure 1A-D).  
ICG clearance is impaired in vivo during APAP-ILI 
To investigate the potential of non- invasive imaging to evaluate liver function during 
APAP-induced liver injury, ICG clearance was monitored in real-time between 3 and 
96 h post-APAP challenge from the ischiatic vessels, by MSOT (Figure 2A-F). 
Compared to vehicle control mice (t1/2= 36.2 s) (Figure A, C), the elimination of ICG 
through the liver of APAP-injured mice was statistically significantly impaired (i.e. 
6h timepoint; t1/2=155.2 s) (Figure 2 B, D). The increase in ICG half- life also 
demonstrated time-dependence, showing a biphasic response with the most elevated 
change observed at 3 h (152.0 ±25.1s), a gradual return to baseline levels by 24 h with 
the second peak observed at 48 h post-APAP treatment (Figure 2E). This trend was 
also seen when ICG clearance was expressed as a function of its rate constant (3 h 
data, 0.004±0.0005 s compared to time matched controls 0.02 ±0.001 s) (Figure 2F). 
By 96 h, ICG-measured clearance was not different to time-matched saline-treated 
controls (Figure 2E-F). 
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To establish a reference model of defined hepatic functional mass and subsequent 
regeneration that correlates with ICG clearance, mice were subjected to a 60% 
hepatectomy. MRI was used to define the actual degree of hepatic mass loss following 
hepatectomy and hepatic regrowth over 7 days (Figure 3 A-D). Active liver 
regeneration was observed from day 2 after surgery onwards, with full recovery in 
hepatic mass by day 10 (data not shown). As a result of 60 % hepatectomy, mice 
showed significantly decreased hepatic function with a peak in MSOT-measured ICG 
half- life occurring at day 2 (236.8 ±35.8 s) compared to sham-operated mice (47.0 
±1.5 s). However, this almost returned to baseline values by day 7 (sFigure 3C). In 
this model, a strong and significant correlation (r = 0.78, P value < 0.0001) was 
observed between MRI-measured hepatic volume and MSOT-derived ICG clearance 
measured at the same time in the same mouse Figure 3D). The liver parenchyma did 
not exhibit any histological changes, neither at the day of surgery nor on day 7 (data 
not shown). 
 
GSH depletion after APAP challenge confirm APAP bioactivation, 
hepatotoxicity and strongly correlates with liver function impairment 
Throughout this study, the expected early depletion in hepatic glutathione (GSH) 
induced by APAP followed by its repletion at late time points was observed (Figure 
4A) (Mitchell et al., 1973). In addition to these, there was also a strong relationship (r 
= -0.63, P value = 0.0007) between APAP-induced GSH depletion and ICG clearance 
kinetics that also reflected individual mouse responses (Figure 4B). 
Relationship between ICG clearance kinetics, circulating biomarkers and 
histopathological scoring during acetaminophen hepatotoxicity 
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To evaluate the utility of MSOT-measured ICG clearance in experimental APAP-ILI, 
we correlated these measurements with quantitative values of circulating mechanistic 
biomarkers and histopathological measures determined at the same time in the same 
animal. At early time points post-APAP treatment (3, 6, 24 h), a strong correlation 
between ICG half- life and all other measured parameters was observed (Table 1). 
Moreover, a strong correlation with cell injury and death, scored by a pathologist, was 
also observed at these early time points (3, 6, and 24 h) (Figure 5). At 48 h, the 
correlation appeared to have disconnected for the circulating biomarkers and ICG 
clearance (Table 1).  
 
Hepato-protective efficacy of NAC is demonstrated by MSOT measured ICG 
clearance kinetics and circulating biomarkers 
NAC represents an effective antidote to liver injury induced by APAP overdose in 
patients that present early to hospital (Antoine and Dear, 2016). To investigate the 
utility of MSOT-measured ICG clearance to assess the efficacy of NAC in 
experimental APAP hepatotoxicity, we treated mice with NAC 1 h after APAP dosing 
and measured hepatic function and toxicity at 6 and 24 h post-APAP. NAC prevented 
the APAP-induced increase in ALT activity and GSH depletion (Figure 6A,E). A 
decrease in ICG half- life at both 6 and 24 h was observed after NAC treatment 
compared to non-NAC treated APAP intoxicated mice (Figure 6F). These data were 
also supported by the reduction in the circulating biomarkers in the NAC-treated 
group when measured at both 6 and 24 h post dosing (Figure 6B-D). The histological 
examination confirmed the findings (Figure 6G). At 6 h post dosing, there was no 
evidence of hepatocyte death (median score 0). The only sign of damage was the 
centrilobular loss of glycogen which was occasionally accompanied by HD of a few 
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hepatocytes in the innermost centrilobular hepatocyte layer (Figure 6G). At 24 h, the 
histological changes were similar to those in APAP-dosed mice without NAC 
treatment, though less severe (median score 1.5) (Figure 6G). These findings suggest 
a delay and reduction of the damage induced by APAP. 
 
Comparison of the loss of liver function measured by MSOT induced by either 
acetaminophen hepatotoxicity or resection 
Within the individual models of hepatic functional impaired used here (APAP or PH), 
we observed a strong and significant relationship between ICG clearance and loss of 
functional parenchyma (APAP: loss of functional parenchyma assessed by histology, 
PH: loss of absolute liver mass loss assessed by MRI). We now sought to determine 
the relative relationship between these models for assessing a defined degree of 
functional liver mass loss that was shown by a qualitative change in MSOT-derived 
ICG clearance. Supplementary figure 2 illustrates the percentage of liver mass loss 
determined either by MRI (PH model) or histopathological examination  (APAP; 3h 
and 24h timepoint), that corresponded to the matched MSOT-measured ICG clearance 
value for the respective models (Supplementary figure 2 A-B).  Interestingly, the early 
degenerative changes (hydropic swelling of centrilobular hepatocytes) at 3 h after 
APAP overdose had a large impact on ICG clearance kinetics compared to the 
massive loss of hepatic mass after 60% PH (Supplementary figure 2 A) and the 
extensive centrilobular necrosis present at 24 h post dosing (Supplementary figure 2 
B). At this time point, the PH model demonstrated significantly lower hepatic 
function than the liver injury induced by APAP when determined by ICG clearance 
(Supplementary figure 2 B). 
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DISCUSSION 
 
Here, for the first time, we report the utility of non- invasive photoacoustic imaging 
and its assimilation with circulating mechanistic biomarkers and traditional methods 
for evaluating hepatic integrity to investigate the onset and recovery from 
experimental acute liver injury using APAP as a paradigm. This “tool box” approach 
can be used to assess the impact of ALI at both the whole organ and hepatocellular 
level, longitudinally, in the same animal.  Our findings reveal a strong and statistically 
significant relationship between the novel and traditional biomarkers of hepatic 
injury, histopathological assessments and functional ICG clearance measured by 
MSOT. These observations provide evidence for the integrated use of these 
parameters to deliver added value and a new dynamic for the preclinical assessment 
of experimental ALI that has potential translational application. 
 
A significant novel aspect to this current report is the assessment of hepatic function, 
in a non-invasive way, by utilising MSOT to measure ICG clearance. MSOT analysis 
permitted the extent of hepatic degeneration and regeneration to be monitored in 
individual mice repeatedly. Here we have used two distinct models that have direct 
clinical relevance and perturb the liver at either the cellular or whole organ level. 
Previous studies have demonstrated the accuracy and reliability of the measurements 
of ICG kinetics for the assessment of liver function in different conditions such as 
liver transplantation or partial resection, amongst others (Imamura et al., 2005; 
Levesque et al., 2016; Pinzani, 2016). The ICG clearance test is a qualitative liver 
function test used during clinical liver surgery and transplantation (Breitenstein et al., 
2009; de Graaf et al., 2010) and has already been used as a prognostic tool to predict 
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survival in sepsis and acute liver failure as well as in critically ill patients (Halle et al., 
2014). For instance, the early non- invasive measurement of ICG was demonstrated to 
accurately predict severe graft dysfunction and mortality after liver transplantation 
(Faybik and Hetz, 2006; Olmedilla et al., 2009). The delay in ICG clearance has been 
explained by a loss in hepatocyte content which consequently reduces the capacity of 
the liver to uptake this compound and excrete it into the gall bladder. A number of 
different techniques have been used to measure ICG and have been associated with 
significant limitations such as cost, time, number of required blood samples and 
invasiveness (Halle et al., 2014; Levesque et al., 2016). Moreover, these limitations 
are further exaggerated when considering the preclinical assessment of hepatic 
impairment. Therefore, the approach we have used offers a significant advantage by 
allowing a real- time and non- invasive measurement of hepatic function in the same 
animal and in a longitudinal manner that correlates with circulating biomarkers of 
liver injury and the histopathological assessment of damage. The multiplicity of 
techniques can be utilised simultaneously to provide different but complementary 
readouts that inform on experimental APAP-ILI in a sensitive and specific manner. 
 
Despite the relative advantages of this approach, it is important to note that this 
strategy is not without limitation. The filtration of ICG is dependent upon blood flow 
(Levesque et al., 2016) and it has been reported that the APAP-ILI model can lead to 
haemodynamic changes (Randle et al., 2008). Therefore, in order to determine that 
our observations regarding ICG kinetics were not misrepresented, we measured the 
blood velocity at 6 and 24 h after APAP treatment using ultrasound and Doppler 
technology (data not shown). Here, no differences in blood velocity were observed 
following APAP treatment in mice compared to controls. This does, however, not 
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exclude that the hydropic swelling of centrilobular hepatocytes at 3 h post APAP 
might have impaired the blood flow at that particular time point. Also, clearance from 
the liver into the gall bladder is known to depend on ATP-dependent transport 
proteins such as ATP-binding cassettes (ABC) (Mrp2 and Mdr2 in mice) (Shinohara 
et al., 1996; Huang and Vore, 2001) and these transporters are known to be up- or 
down-regulated after single or chronic dosing of APAP (Aleksunes et al., 2005; 
Aleksunes et al., 2008). Therefore, it is conceivable that this could impact on data 
interpretation. However, Aleksunes et al (2005) only observed significant up- or 
down-regulation of these transporters at a dose of 400 mg/kg and not at 300 mg/kg. 
Our study has only focused on the acute treatment of mice with APAP (300  mg/kg) 
and we have demonstrated that the measurement of ICG in blood, rather than from the 
gall bladder, does produce robust and reproducible results and correlates with 
mechanistic circulating biomarkers of liver injury. Moreover, the uptake from the 
liver parenchyma is known to be led by non-ATP dependent transporters such as 
organic anion transporters polypeptides (OATP) and Na+-taurocholate co-transporting 
polypeptides (NTCP) (Berk and Stremmel, 1986; de Graaf et al., 2011). Therefore, 
taking into account these factors and the strong association between ICG clearance 
and blood-based biomarkers of toxicity and histopathology, we conclude that our data 
can be interpreted as a result of a decreased capacity of the liver to uptake  and clear 
this dye. The most likely explanation for it is a significant loss of the number of 
functional hepatocytes as a result of the toxic effect of APAP. 
To a greater extent, ICG clearance reflected liver function fluctuations across the time 
course which was imperceptible by the serum biomarkers but was mirrored by 
histological features. An increase of glycogen storage in the hepatocytes from the 
undamaged area was reproduced by a liver function recovery at 24 h time point post-
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
APAP challenge and the inflammatory response, the ongoing cell death and functional 
hepatic mass loss histologically described amongst other features was seen as a 
second peak of liver function impairment at 48 h. Additionally, the disconnection of 
the serum biomarker and ICG half- life correlation also demonstrates the utility of the 
individual parameters in combination and added value that liver function 
measurement adds to the understanding of this phenomenon. This can be rationalized 
by the variability and characteristics of the different biomarkers, such as their half- life 
or time/mechanism of release in the circulation (Giannini et al., 2005). 
The PH model used in this study provided mechanistic insights allowing a better 
understanding and validation of the ICG half- life parameter used as a metric of liver 
function in the onset of APAP induced acute liver injury. Centrilobular cell death has 
been widely reported previously in rodents and humans, with APAP-induced 
hepatotoxicity causing localised, i.e. zonal (centrilobular) hepatocyte death and 
representing a loss of hepatocytes with a specific phenotype and therefore liver 
function (Oinonen and Lindros, 1998; Gujral et al., 2002). This particular type of liver 
function impairment is not reproduced with the PH model in which an entire lobe is 
removed, thereby preserving the integrity of the remaining functional liver. This is 
further demonstrated at early time points post-APAP treatment, in which liver 
function appears to be severely impaired (high ICG half- life values) compared to the 
PH model (Supplementary figure 1 A). At 24 h after APAP treatment, the ICG 
clearance is near basal levels despite sustained necrosis (i.e. effective hepatocytes 
loss) and we could see low ICG half- life values compared to the PH model 
(Supplementary figure 1 B). As mentioned previously this is potentially as a result of 
the compensatory functional response of the unaffected lobular regions (regional 
increase of glycogen storage and GSH levels). The unaffected areas can therefore 
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compensate the metabolic and functional needs of the liver thereby enabling survival. 
Photoacoustic imaging could therefore hold the potential to classify specific types of 
damage related to discrete injury types, non- invasively, when used alongside a panel 
of mechanistic circulating biomarkers. 
 
In conclusion, using APAP as a paradigm, this study demonstrates for the first time 
that the integration of novel non-invasive and dynamic imaging markers of hepatic 
function with mechanistic circulating biomarkers of hepatotoxicity, alongside 
traditional histopathological evaluation, can provide a new way to assess experimental 
hepatotoxicity and its pharmacological restoration that has translational potential. 
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FIGURE AND TABLE LEGENDS 
Table 1. Correlation between circulating biomarkers and ICG kinetics during 
APAP-induced hepatotoxicity in mice. ICG half- life and biomarkers measured after 
APAP challenge at 3 and 6 h strongly correlate with a noticeable disconnection at 24 
and 48 h for ALT, TBIL, miR-122 and HMGB1. Complete disconnection at 72 and 
96 h. Data represents the correlation coefficient r (P value) from the analysis of both 
saline control and APAP treated mice (n = 6-10 per treatment per time point).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Plasma biomarker levels and type and degree of histological changes 
observed during APAP-induced hepatotoxicity in mice . Mice were administered 
with APAP (300 mg/kg) and monitored at 3, 6, 24, 48, 72 and 96 h after dosing. (A) 
ALT increased significantly early and progressively up to 24 h in the serum of APAP-
Time 
Circulating biomarker 
ALT TBIL miR-122 HMGB1 
3 
0.74 
(0.004) 
0.80 
(0.0009) 
0.62  
(0.02) 
0.82 
(0.0006) 
6 
0.76 
(0.002) 
0.53  
(0.05) 
0.70 
(0.005) 
0.56  
(0.04) 
24 
0.49  
(0.06) 
0.60  
(0.02) 
0.03 
(0.92) 
0.73 
(0.004) 
48 
0.07  
(0.85) 
0.17  
(0.63) 
0.07  
(0.85) 
0.0  
(0.55) 
72 
0.76  
(0.01) 
0.21  
(0.55) 
0.32  
(0.36) 
0.63  
(0.05) 
96 
0  
(0.93) 
0.46  
(0.22) 
0  
(0.74) 
0  
(0.84) 
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overdosed mice compared to saline treated (control) mice, (B) TBIL increased early 
significantly in the serum of APAP-overdosed mice and remained elevated compared 
to non-treated mice, (C) miR-122 increased significantly early and progressively up to 
6 h in the serum of APAP-overdosed mice compared to non-treated mice. (D) After 
an early significant increase in total HMGB1 in the serum of APAP-overdosed mice 
compared to non-treated mice values decreased progressively. (A-D) Bars represent 
mean ± standard error of the mean of group of animals (black = control, n = 4-6; 
white = APAP overdose, n = 6-10). Asterisks indicate significance of two-sample t-
tests: p ≤ 0.05 (*), p ≤ 0.005 (**), p ≤ 0.0005 (***).  
(E) Representative HE-stained liver sections from saline treated mice (controls) and 
mice after APAP overdose (3, 6, 24, 48, 72, and 96 h post dosing). At 3 h post APAP, 
the main finding is centrilobular loss of glycogen and HD of hepatocytes in the 
innermost layers (arrows). At 6 and 24 h, centrilobular coagulative necrosis of several 
hepatocyte layers is seen (breadth of necrosis indicated by black line). At 6 h, 
hepatocytes outside affected areas are entirely devoid of glycogen, at 24 h, only 1-2 
hepatocyte layers surrounding the necrotic hepatocytes are devoid of glycogen 
(breadth indicated by short black line), and glycogen has been restituted in the 
remaining parenchyma. At 48 h, the innermost centrilobular areas are comprised of 
(new) glycogen-free hepatocytes intermingled with individual necrotic hepatocytes 
(arrows). At 72 h, there is no evidence of cell death, but centrilobula r areas appear 
less cellular than in controls. The presence of mitotic cells (arrows) indicates 
regeneration. At 96 h, centrilobular areas are more cellular, and there is mild 
leukocyte infiltration around the central vein (arrows). CV = central vein. Bars  = 20 
μm.  
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Figure 2. Parametric maps and quantification of MSOT kinetics. Panels A and B 
show parametric maps for a control mouse (A) and an APAP treated mouse (B), 
where kinetic modelling was performed on a per pixel basis. The elimination rate 
constant is shown in jet as an overlay on a 900nm MSOT image. Blue jet colour 
expresses a low rate constant (K) representative of liver function impairment. 
Contrarily, red pixels describes normal clearance rate of ICG. Pixels which fit poorly 
within the ROI were excluded from the analysis and therefore transparent. The left 
(red) and right (green) ischiatic vessels are shown, as well as vessels surrounding the 
caudal vertebra (orange). Panels C (control) and D (6h time point post-APAP) show 
quantification of spectrally unmixed ICG MSOT signal within the left ischiatic vessel. 
Raw MSOT data was modelled using a single exponential algorithm and shown in red 
in the graph. The average rate constant (K) and half- life (t1/2) for the entire ROI is 
shown as an inset on the graph. Mice were administered with APAP (300 mg/kg) and 
monitored at 3, 6, 24, 48, 72 and 96 h after dosing. (E) Significant increase in ICG 
half- life after APAP-overdose compared to untreated mice up to 72 h, and return to 
baseline values at 96 h. Bars represent mean ± standard error of the mean of group of 
animals (black = control, n = 4-6; white = APAP (300 mg/kg) overdose, n = 6-10). 
(C) Decrease in rate constant after APAP-overdose during the monitoring of liver 
function. (C) Bars represent mean ± standard error of the mean of group of animals (n 
= 5). Asterisks indicate significance in two-sample t-tests: p ≤ 0.05 (*), p ≤ 0.005 
(**). 
Figure 3: Relationship between hepatic mass measured by MRI and hepatic 
function measured by MSOT following partial hepatectomy in mice . Mice 
underwent 60 % hepatectomy or sham surgery and were examined 1, 2, 3 and 7 days 
after surgery. (A) MRI images from a mouse before and after liver resection. (B) 
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Average of liver mass recovery after 60 % hepatectomy from 5 mice during the days 
after surgery. (C) ICG half- life measurements after sham operation and 60 % 
hepatectomy. Bars represent mean ± standard error of the mean of group of animals 
(n=5). Asterisks indicate significance in two-sample t-tests: p ≤ 0.05 (*), p ≤ 0.005 
(**). (D) Scatterplot showing a correlation coefficient of 60 % (r = 0.78, P value < 
0.0001) hepatectomy cohort data between the percentage of liver mass loss and the 
ICG half- life from the ischiatic vessels measurements. Data points represent 
individual animals (triangles = 60 % hepatectomy, n = 5, day 0, 1, 2, 3 and 7 after 
surgery). Trend line for 60 % hepatectomy animals is displayed. 
 
Figure 4: Glutathione measurements after APAP overdose and its correlation 
with ICG kinetics. (A) GSH levels in control compared to APAP treated mice at 3, 6, 
24, 48, 72 and 96 h post injection and (B) correlation between GSH levels from 
different time points and ICG half- life (r = -0.63, P value = 0.0007). (A) Bars 
represent mean ± standard error of the mean of group of animals (black = control, n = 
5; white = APAP (300 mg/kg) overdose, n = 5). Asterisks indicate significance of 
two-sample t-tests: p ≤ 0.05 (*), p ≤ 0.005 (**). 
 Figure 5. Correlation between histopathology score and ICG kinetics during 
APAP-induced hepatotoxicity in mice. The degree of liver degeneration and 
necrosis/cell loss statistically significantly correlates with the delay of ICG clearance 
at 3 h (A), 6 h (B) and 24 h (C) post treatment, however at 48 h (D) this correlation is 
much lower. (E) By 72 h, the ICG clearance has almost returned to control animal 
values, and at 96 h the values in treated and control animals are at the same level. 
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Data points represent individual animals (circles = control, n = 4-5; triangles = APAP-
administered, n = 6-9).  
Figure 6. Impact of NAC on APAP-induced changes in circulating biomarkers 
and ICG kinetics in mice. Mice were administered with APAP (300 mg/kg) and 
received NAC at 1 h post APAP. They were examined at 6 h and 24 h after APAP 
dosing. (A) ALT, (B) TBIL, (C) miR-122 and (D) total HMGB1 serum levels 
decreased in NAC-treated mice compared to non-treated mice. An increase in (E) 
GSH levels in hepatocytes parenchyma anda decrease in (F) ICG half- life was seen 
after NAC treatment relative to APAP-treated mice that did not receive NAC. (G) No 
necrosis was described in the CV area at 6h after NAC treatment and decrease of CV 
necrosis was seen after 24h. (A-F) Bars represent mean ± standard error of the mean 
of group of animals (black = control, n = 4-6; white = APAP (300 mg/kg) overdose, n 
= 5-10).  Asterisks indicate significance in two-sample one way ANOVA (Tukey), 
control vs APAP overdose groups: p ≤ 0.05 (*), p ≤ 0.005 (**), p ≤ 0.0005 (***), p ≤  
0.0001 (****), and hash indicate significance in two-sample on way ANOVA 
(Tukey), APAP overdose vs NAC treated groups p ≤ 0.05 (#), p ≤ 0.005 (##), p ≤  
0.0005 (###), p ≤ 0.0001 (####) .  
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SUPPLEMENTARY MATERIAL AND METHODS 
Dynamic contrast enhanced (DCE) MSOT image generation 
DCE images were generated using a custom-written pharmacokinetic (PK) analysis 
tool from iThera Medical.  A PK model was fitted to image data using an optimization 
routine to minimize the sum of square error between the model-prediction and the 
data.  Based on the assumption of single-phase elimination of _(ICG)_ via _(liver 
clearance)_ pathway, a single exponential decay model was used: 
𝑌(𝑡) = (𝑌0 − 𝑌𝑆𝑆)𝑒
−𝑘∗𝑡 +𝑌𝑆𝑆      
Fitting was run on a per-pixel basis to provide a parametric map of anatomically-
selected ROIs within the image.  Pixels in the DCE image were excluded based on a 
goodness of fit criterion, where pixels yielding an R2 < 0.02 were excluded from the 
DCE image to improve the confidence of values represented in the image. The final 
DCE image is represented as the respective parametric map as an overlay on top of 
representative 900 nm image. 
 
Magnetic resonance imaging (MRI) 
Magnetic resonance imaging (MRI) studies were performed with a 9.4T Bruker 
Biospec 94/20 MRI scanner using a 78 mm body coil transmit and a four-channel 
receive array coil (Bruker Biospin, Inc.). Mice from the PH study were scanned the 
day before surgery and on day 1, 2, 3 and 7 after PH. Mice were anesthetised with 
1.0–2.0 % isoflurane delivered in 1 L/min oxygen gas ventilation before being placed 
on a bed where probes for monitoring rectal temperature and respiration were 
connected to their body. A water-circulating heating pad was placed over the body to 
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maintain a constant temperature of 37 °C during experiments. At the end of scanning, 
the mouse was removed from the scanner, and transferred to the MSOT holder device. 
A T2_TurboRARE MRI sequence was used to acquire the images covering the liver 
in the coronal plane with the following parameters: TR/TE = 2500/24; echo train 
length=8; pixel bandwidth = 446.43; averages = 3; field of view = 30x28 mm; slice 
thickness = 500 µm; slice gap = 100 µm; and in-plane resolution = 125x125 µm. The 
liver in MR images was segmented using ImageJ for liver volume measurements. 
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1. Score for drug-induced liver injury and degenerative 
changes. This figure illustrates the features taken into account for the scoring of liver 
necrosis and hepatocytes undergoing hydropic degeneration. 
Supplementary figure 2. Comparison of the relationship between hepatic 
mass/the extent of liver injury and hepatic function in hepatectomised and 
APAP-overdosed mice. Scatterplot showing a correlation coefficient of the 60 % 
hepatectomy cohort data between the liver mass loss (%) and ICG half- life 
measurements and the correlation coefficient between the APAP-overdosed mice 
score for (A) degenerative changes at 3 h post APAP dosing (r = 0.89, P value = 
0.001) and (B) necrosis at 24 h post dosing (r = 0.63, P value = 0.01) and ICG half-
life measurements. Data points represent individual animals (circles = 60 % 
hepatectomy, n = 5, day 1, 2, 3 and 7 after surgery; triangles = APAP-overdosed 
mice, n = 8-10).  
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HIGHLIGHTS 
 
 Imaging and circulating biomarker “tool box” proposed for liver injury 
and repair 
 Liver function monitored in real time during acetaminophen 
hepatotoxicity 
 Approach based on ICG clearance measured by MSOT 
 ICG kinetics correlates with established methods for liver injury 
detection 
 Approach can be used for prediction of response to therapeutic 
interventions 
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